February 8, 2018 / 8:48 AM / 10 months ago

BUZZ-GSK: gains on new Advair reprieve, HIV drug lawsuit

** GlaxoSmithKline up 2.6% after copy of its blockbuster Advair lung drug from Novartis’s Sandoz division is delayed and GSK takes legal action against Gilead Sciences over new HIV drug

** News helps build confidence after upbeat results presentation Wednesday since competitive threats to respiratory and HIV businesses are key overhangs for stock

** Novartis says 2018 U.S. generic Advair launch by Sandoz “now looks highly unlikely”

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below